arrow
B

Boris S. Naroditsky

national research center for epidemiology and microbiology named after honorary academician n. f. gamaleya
H指数:29
被引数:5,539

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Lethal Pseudofilovirus Model in Ifnar1(-/-) Mice Using Recombinant Vesicular Stomatitis Viruses

利用重组水泡性口炎病毒在Ifnar1(-/-)小鼠中建立的致死性假丝病毒模型

2026-08-110
OA
Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia

GamEvac-Combi,一种异源rVSV-和rAd5载体埃博拉疫苗的安全性与免疫原性:一项在几内亚共和国和俄罗斯进行的随机对照多中心临床试验

2025-03-200
OA
Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5

Sputnik V疫苗在hACE2-Transgenic小鼠中针对同源和异源SARS-CoV-2谱系 (包括远距离Omicron BA.5) 的免疫原性和保护性

2024-10-080
OAAI
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

基于rAd26和rAd5载体的异源初免-加强新型冠状病毒肺炎疫苗对健康青少年SARS-CoV-2的安全性和免疫原性: 一项开放标签、非随机、多中心、1/2期、剂量递增研究

2023-08-014
OAAI
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
2023-03-306
OAAI
Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A
2023-02-1415
OAAI
Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus
2022-11-166
OAAI
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

鼻内递送的基于载体的异源启动-加强新型冠状病毒肺炎疫苗Sputnik V在小鼠和非人灵长类动物中的免疫原性和保护性

2022-09-2610
OAAI
A mechanism of self-lipid endocytosis mediated by the receptor Mincle
2022-07-228
OAAI
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

在Sputnik V疫苗接种的个体中保留针对SARS-CoV-2 Omicron变体的中和反应

2022-05-2120
OAAI
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern

单域抗体可有效中和SARS-CoV-2相关变异

2022-02-2419
OAAI
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults
2021-12-0142
OAAI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

基于rAd26和rAd5载体的异源启动-加强新型冠状病毒肺炎疫苗的安全性和有效性: 俄罗斯一项随机对照3期试验的中期分析

LANCET
IF88.5
2021-02-011.2K
OAAI
Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice
2020-09-1013
OAAI
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

两种制剂中基于rAd26和rAd5载体的异源启动-加强新型冠状病毒肺炎疫苗的安全性和免疫原性: 来自俄罗斯的两项开放,非随机1/2期研究

LANCET
IF88.5
2020-09-01732
OAAI